ABC arbitrage
Half-year liquidity contract statement for ABC ARBITRAGE
Under the liquidity contract entered into between ABC ARBITRAGE and Kepler Cheuvreux, the following resources appeared on the liquidity account on December 31st 2020:
- 18,108 shares
- € 321,693.73
- Number of executions on buy side on semester: 117
- Number of executions on sell side on semester: 140
- Traded volume on buy side on semester: 38,830 shares for € 278,403.87
- Traded volume on sell side on semester: 46,015 shares for € 335,302.51
As a reminder :
• the following resources appeared on the last half year statement on 30 June 2020 on the liquidity account:
- 25,293 shares
- € 264,795.09
- Number of executions on buy side on semester: 302
- Number of executions on sell side on semester: 237
- Traded volume on buy side on semester: 123,471 shares for € 780,442.93
- Traded volume on sell side on semester: 120,852 shares for € 773,959.58
• the following resources appeared on the liquidity account when the activity started:
- 28,440 shares
- € 49,007.93
The liquidity agreement complies with AMF Decision n° 2018-01 dated 2nd July 2018, introducing liquidity agreements on equity securities as permitted market practice.
Contacts :
abc-arbitrage.com
Relations actionnaires : actionnaires@abc-arbitrage.com
Relations presse: VERBATEE / v.sabineu@verbatee.com
EURONEXT Paris - Compartiment B
ISIN : FR0004040608
Reuters BITI.PA / Bloomberg ABCA FP
Attachment
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About Globenewswire
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Genmab A/S18.10.2025 12:00:34 CEST | Press release
Genmab Announces New Data Demonstrating Investigational Rinatabart Sesutecan (Rina-S®) Achieved Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer
F. Hoffmann-La Roche Ltd18.10.2025 07:00:00 CEST | Press release
Roche’s phase III evERA data showed giredestrant significantly improved progression-free survival in people with ER-positive advanced breast cancer
StoneX Group Inc.18.10.2025 01:12:36 CEST | Press release
StoneX Expands Wealth Management Offering for Latin American Clients
F. Hoffmann-La Roche Ltd17.10.2025 22:20:00 CEST | Press release
Roche presents new phase III pivotal data for vamikibart in uveitic macular edema (UME), a serious cause of vision loss
Eavor Technologies Inc.17.10.2025 18:00:00 CEST | Press release
Mark Fitzgerald Appointed President and Chief Executive Officer of Eavor Technologies Inc.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom